Top-News
Montag,
29.06.2020 22:05
von
PR Newswire
| Aufrufe: 93
ReNeuron Announces Further Positive Data in Retinal Clinical Trial
Wirtschaftsnachrichten (Symbolbild).
pixabay.com
PR Newswire
LONDON, June 29, 2020
LONDON, June 29, 2020 /PRNewswire/ -- ReNeuron Group plc (AIM:RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and ultimately blindness.
On February 24, 2020, positive interim efficacy data from patients treated in the Phase 2a study were announced by the Company. The data continued to show a meaningful clinical effect from the therapy at all time-points out to twelve months post-treatment, as measured by the number of letters read on the ETDRS chart (the standardised eye chart used to measure visual acuity in clinical trials).
Since those results were announced, further long-term data from the study have been gathered from patients at six, nine, twelve and now, for the first patient treated, eighteen months follow-up. The Company is pleased to report that the latest data continue to demonstrate the efficacy of the therapy, with a clinically meaningful benefit being observed at all time-points. These results are particularly encouraging as RP is characterized by inexorable progression to blindness, with no therapy currently available for the vast majority of patients.
The results announced on February 24, 2020 excluded two subjects who experienced sight loss as a result of complications arising from the surgical procedure. The Company is pleased to report that one of these two patients has now recovered their vision and is back to at least baseline at one year post treatment.
As previously reported, the degree of efficacy observed varies between patients, with the latest mean results set out in the tables below. The first table shows the latest data including the above-mentioned patient who has recovered to at least the baseline level of vision in the treated eye. The second table shows the latest data excluding both of the patients who originally experienced surgical complications, to provide a comparison against the data previously announced on February 24, 2020.
| Months post-treatment | Mean change from baseline in visual acuity in treated eye* | Mean change from baseline in visual acuity in untreated eye* | Difference in mean change between treated eye and untreated eye* |
| 1 | +7.9 letters (n=9) | +0.2 (n=9) | +7.7 (n=9) |
| 2 | +8.0 letters (n=9) | +1.2 (n=9) | +6.8 (n=9) |
| 3 | +10.8 letters (n=9) | +4.4 (n=9) | +6.4 (n=9) |
| 6 | +9.6 letters (n=9) | +3.4 (n=9) | +6.2 (n=9) |
| 9 | +7.1 letters (n=8) | +1.2 (n=8) | +5.9 (n=8) |
| 12 | +11.9 letters (n=5) | +4.3 (n=5) | +7.6 (n=5) |
| 18 | +17.0 letters (n=1) | +1.0 (n=1) | +16.0 (n=1) |
* Excluding one patient who experienced surgical complications
| Months post-treatment | Mean change from baseline in visual acuity in treated eye* | Mean change from baseline in visual acuity in untreated eye* | Difference in mean change between treated eye and untreated eye* |
| 1 | +11.4 letters (n=8) | +0.3 (n=8) | +11.1 (n=8) |
| 2 | +10.8 letters (n=8) | +1.6 (n=8) | +9.2 (n=8) |
| 3 | +14.0 letters (n=8) | +5.1 (n=8) | +8.9 (n=8) |
| 6 | +12.3 letters (n=8) | +3.4 (n=8) | +8.9 (n=8) |
| 9 | +11.8 letters (n=7) | +1.2 (n=7) | +10.6 (n=7) |
| 12 | +13.4 letters (n=4) | +4.6 (n=4) | +8.8 (n=4) |
| 18 | +17.0 letters (n=1) | +1.0 (n=1) | +16.0 (n=1) |
* Excluding both patients who originally experienced surgical complications
The equivalent data set announced by the Company on February 24, 2020 is as follows:
| Months post-treatment | Mean change from baseline in visual acuity in treated eye* | Mean change from baseline in visual acuity in untreated eye* | Difference in mean change between treated eye and untreated eye* |
| 1 | +11.4 letters (n=8) | +0.3 (n=8) | +11.1 (n=8) |
| 2 | +10.8 letters (n=8) | +1.6 (n=8) | +9.2 (n=8) |
| 3 | +14.0 letters (n=8) | +5.1 (n=8) | +8.9 (n=8) |
| 6 | +15.7 letters (n=6) | +6.5 (n=6) | +9.2 (n=6) |
| 9 | +16.5 letters (n=4) | +6.0 (n=4) | +10.5 (n=4) |
| 12 | +14.3 letters (n=3) Werbung Mehr Nachrichten zur Reneuron Group Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |
